Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Viridian Therapeutics (VRDN) and Enovis (ENOV)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alphatec Holdings (ATEC – Research Report), Viridian Therapeutics (VRDN – Research Report) and Enovis (ENOV – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alphatec Holdings (ATEC)
In a report released today, Caitlin Roberts from Canaccord Genuity maintained a Buy rating on Alphatec Holdings, with a price target of $25.00. The company’s shares closed last Friday at $14.83.
According to TipRanks.com, Roberts is a 3-star analyst with an average return of
Alphatec Holdings has an analyst consensus of Strong Buy, with a price target consensus of $24.33, a 62.2% upside from current levels. In a report issued on January 20, Lake Street also maintained a Buy rating on the stock with a $25.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Viridian Therapeutics (VRDN)
In a report released today, Laura Chico from Wedbush maintained a Buy rating on Viridian Therapeutics, with a price target of $47.00. The company’s shares closed last Friday at $33.00.
According to TipRanks.com, Chico is a 5-star analyst with an average return of
Currently, the analyst consensus on Viridian Therapeutics is a Strong Buy with an average price target of $44.60, which is a 33.7% upside from current levels. In a report issued on January 20, Evercore ISI also maintained a Buy rating on the stock with a $44.00 price target.
Enovis (ENOV)
In a report released today, Caitlin Cronin from Canaccord Genuity maintained a Buy rating on Enovis, with a price target of $50.00. The company’s shares closed last Friday at $22.04.
According to TipRanks.com, Cronin is a 4-star analyst with an average return of
Enovis has an analyst consensus of Strong Buy, with a price target consensus of $45.25, which is a 99.5% upside from current levels. In a report issued on January 22, BTIG also maintained a Buy rating on the stock with a $41.00 price target.
